
Merck will be teaming up with Daiichi Sankyo’s subsidiary Plexxikon to investigate immunotherapy combinations in cancer. A collaborative clinical trial …
Daiichi Sankyo has purchased US-based discovery firm Plexxikon for $805 million, gaining access to its potential blockbuster melanoma drug PLX4032. …
Roche’s mid-stage melanoma candidate has produced positive results in a difficult to treat cancer. RG7204 is an investigational, first-in-class molecule …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

